News

TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development.

The presentations from the 4th International Workshop on Clin. Pharm. of TB Drugs are available [click here].

Key abstracts from ICAAC were:

Authors Abstract Title
  • Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg

Pyrazinamide Increases the Early Bactericidal Activity of TMC207 and PA-824 in Patients with Newly Diagnosed, Smear-positive Pulmonary Tuberculosis
  • A. Diacon, R. Dawson, C. Van Niekerk, N. Erondu, A. Ginsberg
Phase 2 Trial of a Novel 3-Drug Regimen for Both MDR and Drug Sensitive (DS) TB
  • R. Tasneen, S. Li, K. Andries, K. Mdluli, E. Nuermberger
Novel TMC207-containing Regimens Have Sterilizing Activity In Murine Tuberculosis
  • H. Huang , K. Liu, D. Zhang, B. Liu, G. Zhang, H. Zhang, Y. Li, Master C. Zhang, Y. Liu, J. Wang, Y. Lu, M. Zheng, B. Wang, T. Yang, X. Li, C. Li, C. B. Cooper, Z. Ma, D. Yin
SAR of Riminophenazine Class and Discovery of New Anti-tuberculosis Agents Active Against Multidrug-Resistant Tuberculosis
  • Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu, H. Jin, D. Yin, H. Huang, Z. Ma

Clofazimine Analogs with Superior Efficacy against Experimental Tuberculosis and Reduced Potential

for Tissue Discoloration

  • M. Upton, A. Shadiack, Z. Ma, Y. Lu, M. Zheng, B. Wang, L. Fu, W. Zhao, P. Li, J. Xu, H. Zhu,
  • H. Jin, D. Yin, H. Huang
Anti-tubercular Clofazimine Analogs that Demonstrate a Range of Tissue Distribution Patterns Following Eight Weeks Dosing to Mice
  • K. C. Chang, W. W. Yew, S. W. Cheung, C. C. Leung
Extensively Drug-resistant Tuberculosis (XDR-TB) Treated with Daily/ Intermittent Linezolid
  • L. Manzini, M. Parracino, D. Iemmi, G. Lapadula, A. Gori, E. Girardi, C. Mussini
Tolerability of Moxifloxacin as Part of Anti-Tuberculous Treatment

Additional TB R&D News:

Epistem successfully completes first-round testing of TB diagnostic device

Lilly Launches Open Innovation Drug Discovery Platform to Help Find Potential New Medicines Where Medical Need is Great

Open Innovation Drug Discovery [Actual Website]

Drug-Evading Tuberculosis Shows Rising Superbug Threat in China


More News
23 Aug 2022
Last week, the PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...